TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

By R. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B. Johnson, A. Sandler, M. Kris, H. Tran, P. Klein, Xin Li and 3 more. Journal of Clinical Oncology, 2005

1,551 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e4d5cb949d49d2d45531c11e2d166b9412df16fe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. P. Thiery
2. M. Nieto
3. R. Huang
4. H. Acloque
5. D. Stewart
6. William Pao
7. R. Weinberg
8. Jing Yang

In Pulmonary and Respiratory Medicine

1. J. P. Thiery
2. M. Nieto
3. B. Hughes
4. B. Chan
5. R. Huang
6. D. Stewart
7. William Pao
8. R. Weinberg

Citations in the corpus

• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “The INTACT 1 (48) and INTACT 2 (49) looked at gefitinib whereas the TRIBUTE (50) and TALENT (51) trials used erlotinib.”
• Mechanisms of resistance to cisplatin and carboplatin. (2007, background): “[275] Herbst RS, Prager D, Hermann R, et al.”
• Targeting the EGFR signaling pathway in cancer therapy (2012, background): “Erlotinib, when combined with carboplatin/gemcitabine or cisplatin/paclitaxel in two separate randomized Phase III studies did not produce a survival advantage over chemotherapy alone [89-91].”
• Epithelial-mesenchymal transitions in development and disease. (2009, background): “Restoration of E-cadherin can alleviate the resistance to kinase inhibitors (Witta et al., 2006), and a significant response was observed in a Phase 3 clinical trial for E-cadherin positive nonsmall-cell lung carcinoma (Herbst et al., 2005).”
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “95).(87) In the Tarceva Lung Cancer Investigation (TALENT)”